It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin is indicated for use as an anticoagulant in
patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).